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Abstract
Background: Previous work indicates that dilatation of the pulmonary artery (PA) itself or in relation to the
ascending aorta (PA:Ao ratio) predicts pulmonary hypertension (PH). Whether these results also apply for heart
failure with preserved ejection fraction (HFpEF) is unknown.
In the present study we evaluated the diagnostic and prognostic power of PA diameter and PA:Ao ratio on top of
right ventricular (RV) size, function, and septomarginal trabeculation (SMT) thickness by cardiovascular magnetic
resonance (CMR) in HFpEF.
Methods and Results: 159 consecutive HFpEF patients were prospectively enrolled. Of these, 111 underwent CMR
and invasive hemodynamic evaluation.
By invasive assessment 64 % of patients suffered from moderate/severe PH (mean pulmonary artery pressure
(mPAP) ≥30 mmHg). Significant differences between groups with and without moderate/severe PH were observed
with respect to PA diameter (30.9 ± 5.1 mm versus 26 ± 5.1 mm, p < 0.001), PA:Ao ratio (0.93 ± 0.16 versus 0.78 ±
0.14, p < 0.001), and SMT diameter (4.6 ± 1.5 mm versus 3.8 ± 1.2 mm; p = 0.008). The strongest correlation with
mPAP was found for PA:Ao ratio (r = 0.421, p < 0.001). By ROC analysis the best cut-off for the detection of
moderate/severe PH was found for a PA:Ao ratio of 0.83.
Patients were followed for 22.0 ± 14.9 months. By Kaplan Meier analysis event-free survival was significantly worse in
patients with a PA:Ao ratio ≥0.83 (log rank, p = 0.004). By multivariable Cox-regression analysis PA:Ao ratio was
independently associated with event-free survival (p = 0.003).
Conclusion: PA:Ao ratio is an easily measureable noninvasive indicator for the presence and severity of PH in
HFpEF, and it is related with outcome.
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Background
About 50 % of patients presenting with symptoms of
heart failure are diagnosed with heart failure with pre-
served ejection fraction (HFpEF). HFpEF is characterized
by impaired diastolic function due to abnormal relax-
ation of the left ventricle (LV) as well as increased cham-
ber stiffness [1]. The pathophysiology underlying HFpEF
is still incompletely understood. Arterial hypertension,
coronary artery disease and diabetes mellitus seem to
play an important role [2]. The development of post-
capillary pulmonary hypertension (PH) is a common fea-
ture of HFpEF and associated with substantial morbidity
and mortality, frequent hospitalizations and an impaired
quality of life [3–6].
Accurate assessment of PH requires invasive measure-
ment of pulmonary artery (PA) pressure and pulmonary
arterial wedge pressure (PAWP) [7]. Because of the inva-
sive nature of this procedure the majority of HFpEF pa-
tients today are not evaluated by right heart catheter
(RHC). Thus, diagnosis of HFpEF-PH mostly relies upon
echocardiography. The estimation of PA pressure by
echocardiography is a routine measurement, however,
the accuracy of this method is limited [8] and the echo-
cardiographic estimation of pulmonary vascular resistance
is unreliable [9]. Therefore, an alternative straightforward
non-invasive technique in addition to echocardiography is
desirable to predict the likelihood of PH in HFpEF
patients.
Cardiovascular magnetic resonance (CMR) is the
current gold-standard technique to assess right heart di-
mensions, function, wall thickness, as well as the dimen-
sions of the great arteries [10]. Previous work shows that
dilatation of the pulmonary artery (PA) itself or in rela-
tion to the diameter of the ascending aorta (PA:Ao ratio)
predicts PH [11–15]. Furthermore, right ventricular sep-
tomarginal trabeculation (SMT) mass has been identified
as a CMR-derived marker of PH [16].
The present study was intended to determine the use-
fulness and prognostic significance of easily measureable
variables such as PA diameter and PA:Ao ratio on top of
CMR derived right ventricular (RV) dimension, ejection
fraction, SMT dimensions, and RV free wall thickness
(RVFW) in a prospective, well defined HFpEF cohort.
Methods
Study design
This was a prospective observational study performed at
the Medical University of Vienna. All participants gave
written informed consent. The institutional review board
approved the study protocol (EK #796/2010).
Patients
Consecutive patients with suspected HFpEF-PH were in-
vited to participate. HFpEF was diagnosed in the presence
of: (1) symptoms or signs of heart failure; (2) normal or
mildly reduced left ventricular (LV) systolic function (LV
ejection fraction (EF) >50 %); (3) evidence of abnormal LV
relaxation or diastolic stiffness (E/e’ > 8 by echocardiog-
raphy; and (4) NT-proBNP serum levels ≥220 pg/mL [17].
Reasons for exclusion included pacemaker or other condi-
tions precluding patients from CMR, regional wall motion
abnormalities, significant coronary artery disease, signifi-
cant valvular or congenital heart disease, or a glomerular
filtration rate (GFR) below 30 mL/min/1.73m2. All patients
underwent ventilation-perfusion scans and lung function
testing including diffusing capacity of the lung for carbon
monoxide to rule out chronic thromboembolic PH and
PH due to significant lung disease.
Right and left heart catheterization
PAWP, mean pulmonary artery pressure (mPAP), and
cardiac output (CO) were determined. CO was mea-
sured by both thermodilution and Fick method. Simul-
taneously, all patients underwent direct assessment of
LV filling pressures, followed by coronary angiography.
Derived hemodynamic parameters were calculated ac-
cording to standard formulae [18]. PH was diagnosed ac-
cording to recent guidelines as mPAP ≥ 25 mmHg at rest
[19]. PH was classified as moderate or severe when the
mPAP was ≥30 mmHg. The transpulmonary pressure
gradient (TPG) was defined as difference between mPAP
and PAWP and the diastolic pressure gradient (DPG) as
difference between diastolic PA pressure and PAWP.
Cardiovascular magnetic resonance
All CMR studies were performed on a 1.5-T scanner
(Avanto, Siemens Medical Solutions, Erlangen, Germany)
within 30 days of RHC (mean 14.8 ± 9.0 days). Studies
consisted of functional and Late Gadolinium Enhance-
ment (LGE) imaging, according to standard protocols
[20]. For cine imaging, steady state free precision (SSFP)
images were used (repetition time 3.2 ms, echo time
1.2 ms, flip angle 64°, voxel size 1.4 × 1.4 × 6 mm, matrix
180×256). For LGE imaging of the left ventricle, seg-
mented inversion recovery sequences (repetition time:
700 ms, echo time 1.22 ms, flip angle 50°, voxel size 1.4 ×
1.4 ×. 8 mm, matrix 146×256) were acquired 10 min after
injection of 0.1 mmol/kg gadolinium-DTPA (Gadovist®;
Bayer Vital GmbH, Leverkusen, Germany).
PA and Ao diameters were measured from inner-edge
to inner-edge in axial half-Fourier single-shot turbo spin-
echo (HASTE) black blood images (repetition time
810 ms, echo time 43 ms, flip angle 160°, voxel size 1.6 ×
1.6 × 5 mm, matrix 192×256) at the level of the PA bifur-
cation (Fig. 1).
For SMT measurements, cine images were analyzed.
The largest area and the longest medio-lateral diameter
of the septal insertion part of SMT as identified in the
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second or third basal slice of the short axis cine stack
were measured (Fig. 2). The RVFW was measured in
end-diastole in the same short axis image used for SMT
quantification.
All CMR studies were read by two independent ob-
servers blinded to clinical data (GK, SP and JB).
Outcome measures
Patients were prospectively followed by ambulatory visits
and telephone calls at 6-month intervals. The main out-
come measure was a combined endpoint consisting of
hospitalization for heart failure or death from cardiac
causes. Endpoints were ascertained by follow-up visits
and phone calls.
Statistical analysis
Categorical data are presented as total numbers or per-
cent, and continuous variables as mean ± standard devi-
ation. Chi square test or Fisher´s exact test were applied
for categorical variables and the Wilcoxon two-sample
test for continuous variables. Kaplan-Meier estimates
were used to calculate cardiac event rates. Differences
between Kaplan-Meier curves were analyzed using the
log rank test.
Binary logistic regression analysis was used to identify
variables associated with moderate/severe PH (mPAP
≥30 mmHg). In addition, a univariable Cox regression
analysis was used to identify parameters (SMT diameter,
SMT area, RVFW, PA size and PA:Ao ratio) associated
PA 30mm
Ao 33mm
Fig. 1 Example for the measurement of pulmonary artery (PA) and ascending aorta (Ao) diameters in the axial black blood sequence in a patient
with a mean pulmonary artery pressure of 33 mmHg
Fig. 2 Example for the measurement of the septomarginal trabeculation (SMT) diameter and area in an axial cine image in a patient with a mean
pulmonary artery pressure of 33 mmHg
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with event-free survival. In a second step these parameters
were adjusted for potential cofounding clinical variables
such as age, sex, atrial fibrillation, arterial hypertension,
diabetes, chronic obstructive pulmonary disease, and cor-
onary artery disease. All variables with a p-value <0.05 in
the univariable model were entered into a multivariable
model using a stepwise approach. Hazard and odds ratios
for the PA:Ao ratio were reported as PA diameter divided
by Ao diameter times 100. Receiver Operating Character-
istic (ROC) curves were used to determine cut-off values
for the detection of moderate/severe PH. Interobserver
variability was described by using Intra Class Correlation
Coefficients (ICCs). Statistical analyses were performed
with SPSS Statistics version 18 (IBM, Armonk, New York).




Between 2010 and 2013 159 consecutive patients were
enrolled. Of these, 48 had to be excluded from the study
because CMR was not possible due to pacemakers, GFR
<30 mL/min/ 1.73 m2, or claustrophobia. Of the
remaining 111 patients (32.4 % male, 70 ± 9 years old)
who underwent CMR, 64 % suffered from moderate or
severe PH (mPAP ≥ 30 mmHg by RHC). Clinical charac-
teristics, hemodynamic measurements, and CMR parame-
ters of registered patients are summarized in Table 1.
With respect to baseline clinical parameters, patients
with moderate/severe PH more frequently presented with
diabetes (50.0 % versus 23.1 %, p = 0.006), non-significant
coronary artery disease/previous revascularization (27.1 %
versus 5.1 %, p = 0.005); shorter 6-min walk distances
(301 ± 110 m versus 397 ± 104 m, p < 0.001) and had
more dilated left atria (LA; 66.7 ± 9.3 mm versus 62.9 ±
8.7 mm, p = 0.035 for diameters and 33.5 ± 10.2 cm2 ver-
sus 28.3 ± 6.8 cm2, p = 0.005 for areas).
Invasive assessment showed significant differences be-
tween patients with and without moderate/severe PH with
respect to all measured variables except for CO, which
was similar in both groups (5.2 ± 1.2 versus 5.2 ± 1.5 l/min,
p = 0.829).
60 (54 %) patients had a TPG >12 mmHg (formerly
classified as “out-of-proportion PH”) and 13 (12 %) had
a DPG ≥7 mmHg, indicating combined pre- and postca-
pillary pulmonary hypertension [21].
Patients with a TPG >12 mmHg had a significantly
higher PA:Ao ratio as compared to patients with a TPG
≤12 mmHg (0.9 ± 0.2 versus 0.8 ± 0.2, p = 0.001) whereas
PA:Ao ratios did not differ between patients with a DPG
of ≥ and <7 mmHg (0.9 ± 0.2 versus 0.9 ± 0.2, p = 0.230).
However, this lack in statistical significance may be due
to the small proportion of patients with DPGs ≥7 mmHg
(12 % of the study cohort).
LGE was present in 31 % (n = 34) of our patients and
involved 8.8 ± 4.3 % of left ventricular myocardial mass.
In the majority (n = 22), LGE was present at the inser-
tion point of the right ventricle; 8 patients had midmyo-
cardial and 4 subendocardial enhancement. There were
no significant differences in LGE pattern or degree be-
tween groups with and without moderate/severe PH.
Dimensions of the great arteries and indices of right
ventricular hypertrophy for the prediction of moderate/
severe pulmonary hypertension
Dimensions of the great arteries and indices of RV
hypertrophy by CMR are displayed in Table 2. Patients
with moderate/severe PH showed significantly larger PA
diameters than the comparator (30.9 ± 5.1 mm versus
26 ± 5.1 mm, p < 0.001) and also had significantly higher
PA:Ao ratios (0.93 ± 0.2 versus 0.79 ± 0.1, p < 0.001).
SMT diameters (4.6 ± 1.2 mm versus 3.8 ± 1.2 mm, p =
0.008) were larger in patients with moderate/severe PH,
while areas did not differ between groups (p = 0.136).
RVFW showed a wide range from 2.0 to 7.2 mm (4.2 ±
1.1 mm) and did also not differ between patients with and
without moderate/severe PH (p = 0.183). PA:Ao ratio, PA
diameter and SMT diameter were significantly correlated
with mPAP (r= 0.421, p < 0.001; r = 0.401, p < 0.001; r =
0.267, p = 0.005; respectively). Fig. 3 displays the correlation
of PA:Ao ratio with mPAP.
Table 3 shows the binary logistic regression model for
predicting the presence of moderate/severe PH. By uni-
variable analysis, SMT diameter (p = 0.010), PA diameter
(p < 0.001), and PA:Ao ratio (p < 0.001) were associated
with moderate/severe PH. However, by multivariable
analysis only PA:Ao ratio remained independently asso-
ciated with the presence of moderate/severe PH.
By ROC analysis, a PA:Ao ratio of 0.83 was found to
best detect mPAP ≥30 mmHg with a sensitivity of
73.2 % and a specificity of 67.5 %, and an area under the
curve (AUC) of 0.759 (Fig. 4).
Measurements of PA:Ao ratio and PA diameter
showed excellent inter-observer agreement with an Intra
Class Correlation Coefficient (ICC) of 0.815 and 0.905
while ICCs for SMT diameters were only 0.563, and for
RVFW 0.581.
Cardiac outcomes
Patients were followed for 22.0 ± 14.9 months. During
follow-up 40 cardiac events (34 hospitalizations for heart
failure, 6 deaths from cardiovascular causes) occurred.
Table 4 shows the results of the multivariable
Cox-regression model. By univariable analysis, SMT
diameter (p = 0.023), RVFW (p = 0.034), PA diameter
(p = 0.002), and PA:Ao ratio (p = 0.003) were significantly
associated with cardiovascular events. After adjust-
ment for age, sex, atrial fibrillation, diabetes, chronic
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Table 1 Baseline patient characteristics
Variable mPAP < 30 mmHg 40 patients (36 %) mPAP≥ 30 mmHg 71 patients (64 %) All 111 patients p value
Clinical parameters
Age [years] 68.9 ± 10.6 70.6 ± 8.4 70.0 ± 9.3 0.348
Male sex [%] 32.5 32.4 32.4 0.991
BSA [m2] 1.9 ± 0.3 1.9 ± 0.2 1.9 ± 0.2 0.367
AFib [%] 51.3 67.1 61.5 0.103
Diabetes [%] 23.1 50.0 40.4 0.006
HbA1c [%] 5.9 ± 0.6 6.3 ± 1.0 6.2 ± 0.9 0.028
Smoking [%] 33.3 43.3 39.6 0.312
CAD* [%] 5.1 27.1 19.3 0.005
Hypertension [%] 94.9 100.0 98.2 0.056
BMI [kg/m2] 29.3 ± 6.3 31.4 ± 6.0 30.7 ± 6.1 0.079
Heart rate [beats/min] 72.2 ± 14.8 70.8 ± 13.3 71.4 ± 13.8 0.626
6-MWD [m] 396.7 ± 104.3 301.0 ± 110.2 334.4 ± 117.0 <0.001
GFR [mL/min/1.73m2] 64.9 ± 22.7 59.10 ± 17.4 61.0 ± 19.5 0.142
NT-proBNP [pg/ml] 1363.8 ± 2127.4 2252.1 ± 3746.1 1934.8 ± 3278.6 0.171
NYHA 0.081
II [%] 41.0 23.2 29.6
III [%] 56.4 66.7 63.0
IV [%] 2.6 10.1 7.4
Hemodynamic parameters
mPAP [mmHg] 23.9 ± 3.6 39.1 ± 8.0 33.7 ± 10.0 <0.001
sPAP [mmHg] 36.7 ± 6.1 61.5 ± 15.4 52.6 ± 17.5 <0.001
dPAP [mmHg] 15.9 ± 4.0 25.3 ± 6.2 21.9 ± 7.1 <0.001
PAWP [mmHg] 15.5 ± 3.3 22.1 ± 4.3 19.7 ± 5.1 <0.001
LVEDP [mmHg] 16.1 ± 4.6 22.4 ± 6.0 20.3 ± 6.3 <0.001
PVR [dyne*sec/cm5] 134.8 ± 67.4 276.9 ± 125.1 226.5 ± 127.7 <0.001
PAC [ml/mmHg] 3.9 ± 2.1 2.3 ± 0.9 2.9 ± 1.7 <0.001
CO [l/min] 5.3 ± 1.5 5.2 ± 1.2 5.2 ± 1.3 0.829
Cardiovascular magnetic resonance imaging parameters
LV EDD [mm] 46.5 ± 4.7 47.8 ± 6.3 47.3 ± 5.8 0.259
LV EDV [ml] 117.7 ± 33.5 133.5 ± 52.6 127.9 ± 47.1 0.057
LV EDVi [ml/m2] 62.4 ± 18.4 68.3 ± 23.7 66.2 ± 22.0 0.160
LV EF [%] 62.7 ± 10.6 63.3 ± 11.9 63.1 ± 11.4 0.813
LV mass [g] 108.4 ± 37.6 117.5 ± 36.1 113.0 ± 36.8 0.250
IVS [mm] 11.5 ± 2.6 11.6 ± 2.2 11.5 ± 2.3 0.924
LA diameter [mm] 62.9 ± 8.7 66.7 ± 9.3 65.3 ± 9.2 0.035
LA area [cm2] 28.3 ± 6.8 33.5 ± 10.2 31.6 ± 9.4 0.005
RV EDD [mm] 38.9 ± 5.9 40.8 ± 8.1 40.1 ± 7.4 0.193
RV EDV [ml] 143.4 ± 39.6 160.0 ± 67.1 151.3 ± 51.7 0.109
RV EDVi [ml/m2] 76.1 ± 20.7 80.5 ± 29.2 78.9 ± 26.4 0.453
RV EF [%] 50.9 ± 9.1 52.5 ± 11.3 51.9 ± 10.6 0.452
RA diameter [mm] 63.5 ± 8.7 66.7 ± 8.9 65.5 ± 9.0 0.072
RA area [cm2] 28.3 ± 8.9 30.5 ± 8.8 29.7 ± 8.9 0.221
LGE present [%] 25.0 34.8 31.2 0.288
Karakus et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:79 Page 5 of 11
obstructive pulmonary disease and coronary artery
disease, PA diameter (p = 0.003), and PA:Ao ratio
(p = 0.002) remained significant predictors of outcome.
However, after multivariable adjustment, only PA:Ao ra-
tio remained independently associated with event-free
survival.
By Kaplan Meier analysis (Fig. 5), event-free survival
was significantly worse in patients with a PA:Ao ratio
≥0.83 (log rank, p = 0.004).
Discussion
The present study demonstrates that the PA:Ao ratio
can be used as a simple and straight-forward indicator of
PH associated with HFpEF. Moreover, the PA:Ao ratio is
of prognostic value with respect to cardiac events.
In patients suffering from HFpEF right heart variables
are of particular interest as they play an important role
in terms of prognosis [5, 22–27]. Echocardiography is
the first, and often only imaging modality used in HFpEF
patients due to its wide availability. However, the RV is
not easy to examine by echo and considerable inter- and
intraobserver variability exists [9]. Furthermore, estima-
tion of pulmonary hemodynamics may be inaccurate [8].
The definite diagnosis of PH demands invasive RHC to
directly measure PA and wedge pressure, as well as
trans-pulmonary and diastolic pulmonary pressure gra-
dients. Although considered reasonably safe in experi-
enced centers, RHC still carries a risk of morbidity and
mortality [28]. Given the close link between pressures in
the pulmonary circulation and RV dimensions and per-
formance, several right heart imaging parameters have
been shown to indicate the presence of PH [10, 13, 16,
26, 29–35]. CMR has been established as the gold-
standard technique for the assessment of the right heart
[10, 36]. It has the advantage that in addition to accurate
and reproducible evaluation of heart size, function, and
myocardial tissue characterization, CMR allows the as-
sessment of the dimensions of the great arteries.
Indices of right ventricular hypertrophy for the prediction
of pulmonary hypertension
RV mass and RV mass to LV mass ratio (VMI) have
been shown to correlate reasonably well with mPAP in
previous studies [33, 34], but the estimation of RV mass
from CMR images is time-consuming and limited by sig-
nificant inter- and intra-observer variability [16, 32].
Furthermore, it requires dedicated software for off-line
analysis.
RVFW thickness is much more easy to assess than RV
mass or VMI. In a historical series this parameter ap-
peared useful as surrogate marker of PH [30] and was
also shown to be of prognostic value [31]. However, due
to the hypertrabeculated nature of the RV considerable
rater-dependent variation exists for this measurement,
which significantly limits its usefulness [30]. In the
present series, RVFW measurements showed weak re-
producibility and did not differentiate between patients
with and without moderate/severe PH.
Table 1 Baseline patient characteristics (Continued)
Amount of LGE*** [%] 6.8 ± 2.7 9.6 ± 4.7 8.8 ± 4.3 0.093
Subendocardial [%] 0 5.8 3.7 0.294**
Midmyocardial [%] 2.5 10.1 7.3 0.254**
RV insertion point [%] 22.5 18.8 20.2 0.646
BSA indicates body surface area, AFib atrial fibrillation, CAD coronary artery disease, BMI body mass index, 6-MWD six minute walk distance, GFR glomerular
filtration rate, NYHA New York Heart Association functional class, mPAP mean pulmonary artery pressure, sPAP systolic pulmonary artery pressure, dPAP diastolic
pulmonary artery pressure, PAWP pulmonary artery wedge pressure, LVEDP left ventricular end-diastolic pressure, PVR pulmonary vascular resistance, PAC Pulmonary
artery compliance, CO cardiac output, LV left ventricle, EDD end-diastolic diameter, EDV end-diastolic volume, i indexed to body surface area, EF ejection fraction,
IVS interventricular septum thickness, LA left atrium, RV right ventricle, RA right atrium, LGE Late Gadolinium Enhancement
*non-significant coronary artery disease or prior revascularization
**p-values derive from Fisher’s exact test
***Amount of Late Gadolinium Enhancement is given in % of total left ventricular volume
Table 2 Dimensions of the great arteries and indices of right ventricular hypertrophy for the prediction of moderate/severe
pulmonary hypertension
Variable mPAP < 30 mmHg 40 patients (36 %) mPAP≥ 30 mmHg 71 patients (64 %) All 111 patients p-value
PA diameter [mm] 26.3 ± 5.1 30.9 ± 5.1 29.2 ± 5.5 <0.001
Ao diameter [mm] 33.6 ± 4.3 33.4 ± 4.1 33.5 ± 4.1 0.856
PA:Ao ratio 0.79 ± 0.1 0.93 ± 0.2 0.89 ± 0.2 <0.001
SMT diameter [mm] 3.8 ± 1.2 4.6 ± 1.2 4.3 ± 1.4 0.008
SMT area [mm2] 0.96 ± 0.3 1.11 ± 0.5 1.06 ± 0.4 0.136
RVFW [mm] 4.0 ± 1.2 4.3 ± 1.1 4.2 ± 1.2 0.183
PA indicates pulmonary artery, Ao ascending aorta, RVFW right ventricular free wall, SMT septomarginal trabeculation
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The SMT is a prominent muscle band that originates
from the basal ventricular septum and runs apical-laterally
towards the RV free wall [37]. A recent retrospective CMR
study on a small number of patients (n = 49) found that
SMT mass could be a useful marker for the identification
of PH [16]. However, in the present study SMT was hard
to delineate in many patients, leading to significant rater-
dependent variation. Its diagnostic power for the identifi-
cation of patients with moderate/severe PH was clearly in-
ferior as compared to PA:Ao ratio and PA diameter.
Dimensions of the great arteries for the prediction of
pulmonary hypertension
In contrast to the aforementioned parameters (RV myo-
cardial mass, RVFW, SMT), the size of PA and Ao are
easy to measure. Such measurements do not require dedi-
cated software or advanced expertise. In the present study
PA:Ao ratio was identified as the most potent predictor
for the presence of moderate/severe PH. It correlated bet-
ter with mPAP than PA diameter or indices of RV hyper-
trophy and showed excellent reproducibility. In addition,
PA:Ao ratio was independently associated with event-free
survival. From a clinical perspective the differentiation
between isolated post-capillary PH and combined
forms is crucial, in particular with regard to prognosis
[21] and therapeutic consequences. The TPG and DPG
have been introduced to quantify pulmonary vascular dis-
ease occurring as a consequence of PAWP elevation. In
the present study, a greater PA:Ao ratio was predictive for
TPG >12 mmHg.
Several previous studies have evaluated the usefulness
of the PA:Ao ratio for the detection of PH [11–15].
However, only Chan and coworkers report data from a
population with PH due to left heart disease [11]. In that
Fig. 3 Scatter plot showing the correlation between pulmonary artery to ascending aorta (PA:Ao) ratio and mean pulmonary artery pressure
(mPAP; r = 0.421, p < 0.001)
Table 3 Binary logistic regression model for the presence of
moderate/severe pulmonary hypertension (mean pulmonary
artery pressure ≥30 mmHg)
Regr.Coeff. p-value OR 95 % CI for OR
Univariable
SMT area 0.853 0.090 2.346 0.876 6.282
SMT diameter 0.404 0.010 1.498 1.103 2.034
RVFW 0.236 0.200 1.267 0.882 1.818
PA diameter 0.175 <0.001 1.191 1.091 1.301
Ao diamter −0.008 0.875 .992 0.903 1.090
PA:Ao x 100 0.066 <0.001 1.068 1.035 1.103
RVEDV 0.005 0.239 1.005 0.997 1.013
RVEF 0.017 0.377 1.018 0.979 1.058
Multivariable
PA:Ao x 100 0.066 <0.001 1.068 1.035 1.103
SMT indicates septomarginal trabeculation, RVFW right ventricular free wall, PA
pulmonary artery, Ao ascending aorta, RVEDV right ventricular end-diastolic
volume, RVEF right ventricular ejection fraction
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retrospective analysis of 101 patients the authors defined
a PA:Ao ratio cut-off of 0.84 for the detection of PH
(mPAP >25 mmHg), which is in line with our results.
Other studies have used a PA:Ao ratio cut-off of >1.0 for
the suspicion of PH. These included 60 patients with
chronic obstructive pulmonary disease [13], 81 patients
with connective tissue disease [15], 50 patients with mainly
pulmonary disease [14], and a mixed population of 175 pa-
tients [12]. The differences with respect to the PA:Ao cut-
off for the diagnosis of PH may be due to 1) retrospective
design of all aforementioned studies, 2) heterogeneity of
cut-offs for the diagnosis of PH (mPAP >20 mmHg [14]
versus mPAP >25 mmHg [11–13, 15]), 3) heterogeneity of
diagnoses underlying PH, and 4) small patient numbers
[13–15]. Taken together, it remains to be determined
whether the results of the present study are applicable in
patient populations other than HFpEF.
Limitations
Presented data have been collected in a single center set-
ting. Therefore, a center-specific bias cannot be excluded.
However, the major advantages of limiting data collection
to a single center are 1. inclusion of a homogenous patient
population, 2. adherence to a constant clinical routine, 3.
constant quality of echocardiographic and CMR work-up
and 4. constant follow-up.
PA and Ao diameters were acquired from axial HASTE
black blood images and were not planned exactly in line
with the vessel orientation. This may have led to some
over- or underestimation of the vessel size.
Fig. 4 Receiver Operating Characteristics (ROC) curves of pulmonary artery to ascending aorta (PA:Ao) ratio, pulmonary artery (PA) diameter,
septomarginal trabeculation (SMT) diameter and right ventricular free wall thickness (RVFW) with Areas Under the Curve of 0.759, 0.741, 0.652 and
0.576, respectively
Table 4 Univariable, univariable adjusted, and multivariable
adjusted Cox-regression model for cardiovascular events
Regr.Coeff. p-value HR 95.0 % CI
Univariable
SMT area 0.663 0.069 1.941 0.950 3.963
SMT diameter 0.253 0.023 1.287 1.035 1.602
RVFW 0.282 0.034 1.326 1.022 1.720
PA diameter 0.093 0.002 1.097 1.035 1.163
PA:Ao x 100 0.027 0.003 1.027 1.010 1.046
RVEDV 0.003 0.365 1.003 0.997 1.009
RVEF −0.016 0.340 0.985 0.954 1.017
Adjusted*
SMT area 0.500 0.180 1.650 0.793 3.430
SMT diameter 0.233 0.060 1.262 0.990 1.608
RVFW 0.357 0.052 1.428 0.997 2.047
PA diameter 0.126 0.003 1.135 1.044 1.233
PA:Ao x 100 0.034 0.002 1.035 1.013 1.057
RVEDV 0.004 0.298 1.004 0.997 1.011
RVEF −0.032 0.095 0.968 0.933 1.006
Multivariable, adjusted*
PA:Ao x 100 0.031 0.003 1.031 1.010 1.053
SMT indicates septomarginal trabeculation, RVFW right ventricular free wall, PA
pulmonary artery, Ao ascending aorta, RVEDV right ventricular
end-diastolic volume
*Adjusted for age, sex, atrial fibrillation, diabetes, chronic obstructive
pulmonary disease and coronary artery disease
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The majority of patients included in this study were
suffering from PH (83.8 % had mPAP ≥25 mmHg). Sixty
four percent had at least moderate PH (mPAP
≥30 mmHg). Due to the small number of patients in the
group without PH, patients were dichotomized in groups
with mPAPs above and below 30 mmHg, defined as
groups with no/mild PH versus moderate/severe PH.
However, previous work shows that a PA:Ao ratio of
0.84 also discriminates between patients with mPAPs
above and below 25 mmHg [11]. In addition to morpho-
logical indicators of right heart pressure overload, recent
data indicate the feasibility of CMR to estimate pulmon-
ary hemodynamics, such as mPAP and pulmonary vascu-
lar resistance by using numerical models [35]. Such
estimates, however, include various assumptions. Further-
more, they require extensive experience of the investiga-
tor. Thus, the accuracy and widespread applicability of
these measurements still need to be proven. Furthermore,
we did not analyse RV mass, which might have aug-
mented the diagnostic performance of the PA:Ao ratio.
However, in the present work we aimed to identify pa-
rameters that are easy to measure and do not require
dedicated software or extensive training.
Conclusions
PA:Ao ratio is an easily assessable, straight-forward
marker of PH in HFpEF patients. Moreover, it is strongly
associated with outcome. Other CMR derived indices of
RV pressure overload such as RVFW or SMT thickness
are less accurate and reproducible.
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